Myriad Genetics Inc at Goldman Sachs Global Healthcare Conference Transcript
Thanks for being here. I'm Patrick Donnelly, the tools and diagnostics analyst here at Goldman. Glad to have Mark Capone, the CEO of Myriad with us today. We have about 35 minutes. Certainly open for Q&A. So if anyone has any questions, just raise your hand, I'll try to get to you.
But Mark, maybe just to start, maybe you can just kind of recap the most recent quarter, the moving pieces coming out of that, and then we can dive in.
Yes. I think one of the things -- and thanks, Patrick. Great conference as always. Thank you to Goldman.
One of the things we've been very focused on as a company is our strategy has been to establish a solid hereditary cancer foundation and then build the number of new products on top of that, and we continue to make very good progress with that strategy. I think in the most recent quarter, 76% of our volume was attributed to those new products, where
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |